The "MPDZ Gene Hydrocephalus Nonsyndromic Autosomal Recessive Type 2 Genetic Test" is a specialized diagnostic assessment offered by DNA Labs UAE, designed to identify mutations in the MPDZ gene, which have been linked to the development of nonsyndromic autosomal recessive type 2 hydrocephalus. Hydrocephalus is a condition characterized by an abnormal accumulation of cerebrospinal fluid (CSF) within the ventricles of the brain, which can lead to increased intracranial pressure, and in severe cases, brain damage. The condition described as nonsyndromic does not present with other syndromic features, making genetic testing crucial for accurate diagnosis.
The MPDZ gene plays a significant role in cellular functions that are critical for brain development and the regulation of fluid channels, which, when mutated, can disrupt normal CSF flow, leading to hydrocephalus. The genetic test involves analyzing the patient's DNA to detect mutations in the MPDZ gene that are responsible for this specific type of hydrocephalus. This test is particularly important for families with a history of the condition, as it follows an autosomal recessive inheritance pattern, meaning that two copies of the mutated gene (one from each parent) are necessary for a child to be affected.
DNA Labs UAE offers this genetic test at a cost of 4400 AED. The test is conducted in their state-of-the-art laboratory facilities, where they utilize the latest in genetic testing technology to ensure accurate and reliable results. This test not only aids in the diagnosis of affected individuals but also provides crucial information for families regarding future pregnancies and the risk of recurrence of the condition. Additionally, early diagnosis through genetic testing can facilitate timely intervention and management of the condition, potentially improving outcomes for those affected.
The GLRA1 Gene Hyperekplexia Genetic Test is a specialized diagnostic tool designed to identify mutations in the GLRA1 gene, which are linked to hyperekplexia, a rare genetic disorder. Hyperekplexia, also known as startle disease, is characterized by an exaggerated startle response to unexpected stimuli. This condition can vary in severity, from mild startles to severe stiffness and falls, and in some cases, it can lead to serious health complications, especially in infants.
The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for any genetic abnormalities in the GLRA1 gene. Identifying mutations in this gene can confirm a diagnosis of hyperekplexia, enabling healthcare providers to offer appropriate treatment and management strategies for the condition.
This specific genetic test is available at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The cost of the GLRA1 Gene Hyperekplexia Genetic Test at DNA Labs UAE is 4400 AED. Given the complexity and the specialized nature of this test, it represents a critical step towards personalized medicine for patients exhibiting symptoms of hypereklexia, providing them with a clear diagnosis and paving the way for targeted interventions.
The GLRB gene hyperekplexia genetic test is a specialized diagnostic examination offered by DNA Labs UAE, designed to identify mutations in the GLRB gene, which are associated with hyperekplexia. Hyperekplexia, also known as startle disease, is a rare genetic disorder characterized by an exaggerated startle response to sudden stimuli, muscle stiffness, and, in severe cases, apnea and sudden infant death. This condition is primarily inherited in an autosomal dominant or recessive manner, making the identification of genetic mutations critical for diagnosis, treatment planning, and genetic counseling.
DNA Labs UAE employs cutting-edge genetic sequencing technology to analyze the GLRB gene, ensuring accurate and reliable results. The test is conducted with a simple blood sample or cheek swab, making it non-invasive and straightforward for patients. Upon completion, the results provide essential information regarding the presence of specific gene mutations, aiding in the confirmation of a hyperekplexia diagnosis and facilitating a better understanding of the condition's potential impact on the patient and their family.
The cost of the GLRB gene hyperekplexia genetic test at DNA Labs UAE is 4400 AED. While the price may seem significant, the value of obtaining a precise diagnosis and the benefits it brings in terms of targeted treatment and family planning cannot be understated. For families and individuals facing symptoms indicative of hyperekplexia, this test represents a crucial step towards achieving clarity and taking informed actions for managing the condition.
The SLC6A5 gene hyperekplexia genetic test is a specialized diagnostic tool designed to identify mutations in the SLC6A5 gene, which are known to cause hyperekplexia. Hyperekplexia, also known as startle disease, is a rare genetic disorder characterized by an exaggerated startle response to sudden stimuli, stiffness, and, in severe cases, apnea and sudden infant death. The condition is primarily inherited in an autosomal dominant manner, though autosomal recessive inheritance has also been observed.
The test involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed to detect any genetic alterations in the SLC6A5 gene. Identifying these mutations can confirm a diagnosis of hyperekplexia, allowing for appropriate management and treatment of the condition. It can also provide valuable information for family planning and genetic counseling for affected families.
In the UAE, this specific genetic test is available at DNA Labs UAE, a leading facility in genetic testing and personalized medicine. The cost of the SLC6A5 gene hyperekplexia genetic test at DNA Labs UAE is set at 4400 AED. This test is crucial for individuals with a family history of hyperekplexia or those exhibiting symptoms of the disorder, providing them with a definitive diagnosis and guiding their treatment plans.
The ARHGEF9 gene is associated with a range of neurological disorders, including hyperekplexia and Early Infantile Epileptic Encephalopathy 8 (EIEE8). Hyperekplexia is characterized by an exaggerated startle response to unexpected stimuli, while EIEE8 is a severe form of epilepsy that presents in infancy, often leading to developmental delays and intellectual disability. Mutations in the ARHGEF9 gene disrupt the normal functioning of inhibitory synapses in the brain, leading to these conditions.
To diagnose and understand these conditions better, genetic testing targeting the ARHGEF9 gene can be conducted. DNA Labs UAE offers a comprehensive ARHGEF9 Gene Hyperekplexia EIEE8 Related Genetic Test. This test is designed to identify mutations in the ARHGEF9 gene that are known to cause hyperekplexia and EIEE8, providing essential information for accurate diagnosis and management of the conditions.
The cost of the ARHGEF9 Gene Hyperekplexia EIEE8 Related Genetic Test at DNA Labs UAE is 4400 AED. The test involves collecting a DNA sample, typically through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the ARHGEF9 gene. Results from this test can guide healthcare providers in developing a tailored treatment plan for affected individuals and offer families important insights into the genetic nature of these conditions.
The SCN4A gene hyperkalemic periodic paralysis genetic test is a specialized diagnostic procedure aimed at identifying mutations in the SCN4A gene, which are associated with hyperkalemic periodic paralysis (HyperPP). HyperPP is a rare genetic disorder characterized by episodes of muscle weakness or paralysis, often triggered by elevated potassium levels in the blood. The condition is inherited in an autosomal dominant manner, meaning a mutation in just one of the two copies of the gene can cause the disorder.
This test is crucial for individuals who exhibit symptoms of HyperPP or have a family history of the condition, as it can provide a definitive diagnosis. Early identification of the disorder is vital for managing symptoms, preventing potential complications, and making informed decisions about family planning.
The test is available at DNA Labs UAE, a reputable facility known for its advanced genetic testing services. The cost of the SCN4A gene hyperkalemic periodic paralysis genetic test is 4400 AED. The test involves collecting a DNA sample, usually through a blood draw or a cheek swab, which is then analyzed in the laboratory for the presence of mutations in the SCN4A gene.
Upon completion, the results can offer critical insights into the genetic underpinnings of the individual's condition, enabling personalized treatment plans and lifestyle adjustments to better manage the symptoms of hyperkalemic periodic paralysis.
The GCH1 Gene Hyperphenylalaninemia BH4-Deficient B Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to detect mutations in the GCH1 gene, which are associated with BH4-deficient Hyperphenylalaninemia (HPA) type B. This condition is a rare metabolic disorder characterized by elevated levels of phenylalanine in the blood, due to a deficiency in tetrahydrobiopterin (BH4), a cofactor essential for the metabolism of several amino acids, including phenylalanine. Early detection and treatment are crucial to prevent developmental delays and neurological issues associated with the condition.
The test involves analyzing the patient's DNA to identify any genetic variations in the GCH1 gene that may lead to the dysfunction of BH4 synthesis. It is a critical tool for clinicians in the diagnosis and management of patients with suspected BH4-deficient Hyperphenylalaninemia, allowing for timely intervention and personalized treatment plans.
DNA Labs UAE offers this comprehensive genetic testing service at a cost of 4400 AED. The test is conducted in their state-of-the-art facilities, ensuring high-quality, reliable results for patients and healthcare providers.
The CACNA1S gene hypokalemic periodic paralysis type 1 genetic test is a specialized diagnostic tool used to identify mutations in the CACNA1S gene, which are linked to hypokalemic periodic paralysis type 1 (HypoPP1). This condition is characterized by episodes of muscle weakness or paralysis, often triggered by factors such as rest after exercise, high carbohydrate meals, or stress, due to abnormally low levels of potassium in the blood (hypokalemia). The test is crucial for confirming the diagnosis, allowing for appropriate management and treatment strategies to be implemented.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test involves analyzing the patient's DNA sample, typically collected through a blood draw, to search for specific genetic alterations in the CACNA1S gene known to cause the disorder. The presence of these mutations can confirm the diagnosis of HypoPP1, enabling affected individuals and their families to receive tailored advice on managing the condition, including preventive measures for avoiding triggers and potential treatments to alleviate symptoms.
The cost of the CACNA1S gene hypokalemic periodic paralysis type 1 genetic test at DNA Labs UAE is 4400 AED. This price reflects the sophisticated technology and expertise required to accurately identify mutations in the CACNA1S gene and provide individuals with reliable results. By opting for this test, patients gain crucial insights into their condition, empowering them with the knowledge needed to manage their health effectively.
The "DARS Gene Hypomyelination with Brainstem and Spinal Cord Involvement and Leg Spasticity Genetic Test" is a specialized diagnostic tool available at DNA Labs UAE, designed to detect mutations in the DARS gene. These mutations are known to cause a rare neurological disorder characterized by underdevelopment of the myelin sheath (hypomyelination) in the brainstem and spinal cord, leading to symptoms such as leg spasticity, difficulty in movement, and other related neurological impairments. The test is crucial for early diagnosis and management of the condition, providing essential genetic information that can guide treatment options and inform family planning decisions. Priced at 4400 AED, this genetic test represents a significant step forward in the personalized care and management of patients with this rare condition, offering hope for improved quality of life through targeted interventions.
The GNE Gene Inclusion Body Myopathy Genetic Test is a specialized diagnostic tool used to detect mutations in the GNE gene, which are responsible for a rare genetic disorder known as Inclusion Body Myopathy 2 (IBM2), also referred to as GNE Myopathy or Nonaka Myopathy. This condition is characterized by progressive muscle weakness and wasting, primarily affecting the lower limbs initially and then progressing to involve upper limbs and other muscle groups.
The test is conducted at DNA Labs UAE, a reputable facility known for its advanced genetic testing capabilities. By analyzing a patient's DNA sample, usually obtained through a blood draw, the test identifies specific mutations in the GNE gene that cause the disorder. This precise genetic insight is crucial for confirming a diagnosis, which can then guide treatment decisions, inform patients about the progression of the disease, and help families understand the risk of inheritance.
The cost of the GNE Gene Inclusion Body Myopathy Genetic Test at DNA Labs UAE is 4400 AED. While the price may seem steep, the value of obtaining a definitive diagnosis and the potential to tailor a patient's care plan specifically to their genetic makeup makes it a worthwhile investment for those affected by this condition. Early diagnosis through genetic testing can significantly impact the management of the disease and improve the quality of life for individuals with GNE Myopathy.
